Ida Hansen is the advisor of the company. Ida has completed her business education from BI Norwegian Business School which is an esteemed institution in Norway and second larges in all the Europe. She is a an entrepreneur herself and has long experiences in problem solving across Norway and Scandinavia. She is also the founder and CEO of Wileo AS i Norge. She has joined us for a good cause to save lives of Norwegian Cancer Patients with Kreft Presisjons Medisin, Diagnostisering og Forskning.
Professor Morten is the advisor of the company. He has completed his doctorate degree in management from Skema Business School, France. His key areas are value creation and investment projects for the businesses. He is currently a professor at SKEMA and teaches / supervises PhD and Master students. As an experienced leader as well as c-suite advisor, his core expertise are within consulting, investments (projects, start-ups and PE), M&A, turnarounds and transformations (including digital transformation), as well as corporate strategy and business development. He is also a keynote speaker and an artist.
Tore H Rismyhr
Tore Rismyhr is the advisor of the company. Tore is in the board of directors at Airthings ASA. He has completed his business education from BI Norwegian Business School in Norway. His wide experience includes in establishing and managing sales organisations, both operational and administrative, excellence in relationships at all levels, and possess a blend of experience and tech savviness within IoT, proptech, welfare technology and creative use of tech. He has joined us with a passion to contribute in helping cancer patients using Kreft Presisjonsmedisin og Forskning.
Professor Klaus H. Beiske, MD, PhD
Professor Klaus is the advisor of the company. He is a professor at institute of clinical medicine, university of Oslo and department of pathology, Oslo university hospital, Oslo, Norway. He is also a renowned clinician and cancer researcher across Europe (European Paediatric Cancer Congress) for translational and computational research on solid and hematological cancer. He has life long experiences in cancer research and pathology including pathology, chemo- therapy resistance, genomics and genetic diagnosis.
Charitra Kumar Mishra, PhD
Founder and CEO